SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

LXRX

Lexicon Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming clinical data readouts and potential achievement of the third $10 million milestone later in 2026. The partnership with Novo Nordisk de-risks development and validates LX9851's potential, supporting upside in Lexicon's valuation despite its small market cap.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.64
T+0 close · Mar 23, 2026 · via day close
Latest settled
+24.39%
T+60 · $2.04
Vs SPY
+11.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $1.64entry
  2. T+1 · 8mo ago +4.88%α +5.23% · $1.72
  3. T+5 · 8mo ago −7.93%α −4.36% · $1.51
  4. T+20 · 7mo ago +11.59%α +4.17% · $1.83
  5. T+60 · 5mo ago +24.39%α +11.33% · $2.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class oral obesity candidate discovered by Lexicon. As a result, Lexicon earned a $10 million milestone payment and remains eligible for up to $1 billion in total milestones plus royalties on future sales.

Key Financial Metrics

Deal Value
$1.0B

Key Facts

  • Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon.
  • Lexicon is eligible for up to $1 billion in total upfront and milestone payments, including a third $10 million milestone potentially this year.
  • LX9851 is a novel oral non-incretin drug targeting obesity with preclinical data showing enhanced weight loss when combined with semaglutide.
  • The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity, with completion expected in Q1 2027.

Financial Impact

$10 million received in 2026, with potential for up to $1 billion in total milestones and tiered royalties on future sales

cash_positionrevenue_potentialvaluation

Risk Factors

  • Future milestone payments and royalties depend on successful development and regulatory approval, which are uncertain.
  • Competition in the obesity pharmacotherapy space is intensifying with GLP-1-based therapies dominating the market.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260282

Track record

16 reports on LXRX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026